Characteristics of patients with MPN-AP/BP treated with intensive chemotherapy, DNMTi-based therapy, and DNMTi + VEN–based therapy
| Variable, mean (SD) . | IC (n = 65) . | DNMTi + VEN–based (n = 54) . | DNMTi-based (n = 65) . | P value . |
|---|---|---|---|---|
| Age (y) at diagnosis of MPN-AP/BP | 62.9 (8.6) | 71.2 (7.4) | 69.7 (10.5) | <.0001∗ |
| WBC (103/μL) | 17.6 (21.5) | 23.5 (26.4) | 21.8 (33.1) | .48∗ |
| Platelet (103/μL) | 188.7 (287.4) | 184.4 (203.8) | 235.5 (330.1) | .54∗ |
| Hemoglobin (g/dL) | 9.3 (2.2) | 8.9 (1.9) | 8.8 (1.6) | .33∗ |
| Peripheral blasts (%) | 24.5 (22.9) | 21.0 (22.9) | 13.5 (14.4) | .009∗ |
| Marrow blasts (%) | 36.8 (22.1) | 34.6 (23.9) | 21.9 (19.0) | .0006∗ |
| Total bilirubin (g/dL) | 0.8 (0.6) | 0.8 (0.4) | 0.9 (0.5) | .70∗ |
| Creatinine (g/dL) | 1.0 (0.3) | 1.2 (0.5) | 1.0 (0.9) | .15∗ |
| Splenomegaly | 30 (48.4) | 21 (39.6) | 39 (61.9) | .052 |
| Chronic-phase MPN | ||||
| Polycythemia vera | 14 (21.5) | 9 (16.7) | 14 (21.5) | .22 |
| Essential thrombocythemia | 22 (33.9) | 15 (27.8) | 17 (26.2) | |
| Primary myelofibrosis | 13 (20.0) | 18 (33.3) | 26 (40.0) | |
| Other | 16 (24.6) | 12 (22.2) | 8 (12.3) | |
| Driver mutation | ||||
| JAK2 | 37 (56.9) | 38 (70.4) | 39 (60.0) | .30 |
| CALR | 9 (13.9) | 7 (13.0) | 13 (20.0) | .50 |
| MPL | 8 (12.3) | 6 (11.1) | 5 (7.7) | .67 |
| Triple-negative | 13 (20.0) | 4 (7.4) | 10 (15.4) | .15 |
| Mutations | ||||
| ASXL1 | 13 (20.0) | 16 (29.6) | 16 (24.6) | .48 |
| EZH2 | 4 (6.2) | 3 (5.6) | 7 (10.8) | .61† |
| SRSF2 | 7 (10.8) | 19 (35.2) | 8 (12.3) | .0008 |
| IDH1 | 3 (4.6) | 3 (5.6) | 4 (6.2) | 1.00† |
| IDH2 | 7 (10.8) | 6 (11.1) | 6 (9.2) | .94 |
| U2AF1 | 4 (6.2) | 5 (9.3) | 3 (4.6) | .66† |
| RUNX1 | 7 (10.8) | 11 (20.4) | 8 (12.3) | .28 |
| TP53 | 11 (15.9) | 13 (24.1) | 14 (21.5) | .62 |
| Variable, mean (SD) . | IC (n = 65) . | DNMTi + VEN–based (n = 54) . | DNMTi-based (n = 65) . | P value . |
|---|---|---|---|---|
| Age (y) at diagnosis of MPN-AP/BP | 62.9 (8.6) | 71.2 (7.4) | 69.7 (10.5) | <.0001∗ |
| WBC (103/μL) | 17.6 (21.5) | 23.5 (26.4) | 21.8 (33.1) | .48∗ |
| Platelet (103/μL) | 188.7 (287.4) | 184.4 (203.8) | 235.5 (330.1) | .54∗ |
| Hemoglobin (g/dL) | 9.3 (2.2) | 8.9 (1.9) | 8.8 (1.6) | .33∗ |
| Peripheral blasts (%) | 24.5 (22.9) | 21.0 (22.9) | 13.5 (14.4) | .009∗ |
| Marrow blasts (%) | 36.8 (22.1) | 34.6 (23.9) | 21.9 (19.0) | .0006∗ |
| Total bilirubin (g/dL) | 0.8 (0.6) | 0.8 (0.4) | 0.9 (0.5) | .70∗ |
| Creatinine (g/dL) | 1.0 (0.3) | 1.2 (0.5) | 1.0 (0.9) | .15∗ |
| Splenomegaly | 30 (48.4) | 21 (39.6) | 39 (61.9) | .052 |
| Chronic-phase MPN | ||||
| Polycythemia vera | 14 (21.5) | 9 (16.7) | 14 (21.5) | .22 |
| Essential thrombocythemia | 22 (33.9) | 15 (27.8) | 17 (26.2) | |
| Primary myelofibrosis | 13 (20.0) | 18 (33.3) | 26 (40.0) | |
| Other | 16 (24.6) | 12 (22.2) | 8 (12.3) | |
| Driver mutation | ||||
| JAK2 | 37 (56.9) | 38 (70.4) | 39 (60.0) | .30 |
| CALR | 9 (13.9) | 7 (13.0) | 13 (20.0) | .50 |
| MPL | 8 (12.3) | 6 (11.1) | 5 (7.7) | .67 |
| Triple-negative | 13 (20.0) | 4 (7.4) | 10 (15.4) | .15 |
| Mutations | ||||
| ASXL1 | 13 (20.0) | 16 (29.6) | 16 (24.6) | .48 |
| EZH2 | 4 (6.2) | 3 (5.6) | 7 (10.8) | .61† |
| SRSF2 | 7 (10.8) | 19 (35.2) | 8 (12.3) | .0008 |
| IDH1 | 3 (4.6) | 3 (5.6) | 4 (6.2) | 1.00† |
| IDH2 | 7 (10.8) | 6 (11.1) | 6 (9.2) | .94 |
| U2AF1 | 4 (6.2) | 5 (9.3) | 3 (4.6) | .66† |
| RUNX1 | 7 (10.8) | 11 (20.4) | 8 (12.3) | .28 |
| TP53 | 11 (15.9) | 13 (24.1) | 14 (21.5) | .62 |